Therapeutic effect of dipeptidyl peptidase-4 inhibitor on patients with type 2 diabetes mellitus with nonalco-holic fatty liver disease
10.3969/j.issn.1006-5725.2017.13.024
- VernacularTitle:二肽基肽酶Ⅳ抑制剂对2型糖尿病合并非酒精性脂肪肝患者的治疗作用
- Author:
Yeli ZHANG
;
Leiqun LU
;
Xiaoying MA
;
Ying SHEN
;
Ping GAO
;
Xi GU
;
Xiaolan DU
;
Ling CHEN
- Keywords:
type 2 diabetes mellitus;
nonalcoholic fatty liver disease;
dipeptidyl peptidase-4 inhibitor
- From:
The Journal of Practical Medicine
2017;33(13):2160-2164
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore therapeutic effect of dipeptidyl peptidase IV inhibitor on type 2 diabetes mellitus with nonalcoholic fatty liver disease. Methods 120 patients suffering type 2 diabetes mellitus with nonal-coholic fatty liver disease from October 2014 to March 2016 in our hospital were randomly divided into two groups:treatment group and control group. Both groups were given type 2 diabetes conventional treatment ,and the treat-ment group was given dipeptidyl peptidase IV inhibitor in addition. Height,weight,waist circumference,hip cir-cumference were measured. Lipid metabolism and,function index,FPG,2 h PG,HbA1c,Ins,C peptide were detected. HOMA-IR was calculated. Results The total effective rate of clinical treatment of fatty liver in the treat-ment group(88.3%)was higher than the control group(78.3%). The difference was statistically significant. FPG , 2hPG,HbA1c,HOMA-IR,LDL-C,TC,TG,AST,ALT andγ-GT in the treatment group were lower than the con-trol group. The difference was also statistically significant. Conclusion The efficacy of sitagliptin in the treatment of type 2 diabetes with nonalcoholic fatty liver was significant. It can also significantly reduce blood glucose and in-sulin resistance. Furthermore ,it has a better effect on the patients with blood glucose control and lipid metabolism regulation.
